Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 8:6:29606.
doi: 10.1038/srep29606.

Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study

Shu-Yu Tai  1   2   3   4   5 , Shu-Pin Huang  6   7   8 , Bo-Ying Bao  9   10   11 , Ming-Tsang Wu  4   5   12   13
Affiliations

Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study

Shu-Yu Tai et al. Sci Rep. .

Abstract

The circadian-related hormones, melatonin and cortisol, have oncostatic and immunosuppressive properties. This study examined the relationship between these two biomarkers and the presence of prostate cancer. We measured their major metabolites in urine collected from 120 newly diagnosed prostate cancer patients and 240 age-matched controls from January 2011 to April 2014. Compared with patients with lower urinary melatonin-sulfate or melatonin-sulfate/cortisol (MT/C) ratio levels, those with above-median levels were significantly less likely to have prostate cancer (adjusted OR (aOR) = 0.59, 95% CI = 0.35-0.99; aOR = 0.46, 95% CI: 0.27-0.77) or advanced stage prostate cancer (aOR = 0.49, 95% CI = 0.26-0.89; aOR = 0.33, 95% CI = 0.17-0.62). The combined effect of both low MT/C ratios and PSA levels exceeding 10 ng/ml was an 8.82-fold greater likelihood of prostate cancer and a 32.06-fold greater likelihood of advanced stage prostate cancer, compared to those with both high MT/C ratios and PSA levels less than 10 ng/ml. In conclusion, patients with high melatonin-sulfate levels or a high MT/C ratio were less likely to have prostate cancer or advanced stage prostate. Besides, a finding of a low MT/C ratio combined with a PSA level exceeding 10 ng/ml showed the greatest potential in detecting prostate cancer and advanced stage prostate cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Urinary biomarkers of circadian hormone between case and control groups.
(a) melatonin; (b) cortisol; (c) ratio of melatonin/cortisol.
See this image and copyright information in PMC

References

    1. Blask D., Dauchy R. & Sauer L. Putting cancer to sleep at night. Endocr. 27, 179–188 (2005). - PubMed
    1. Brzezinski A. Melatonin in humans. N. Engl. J. Med. 336, 186–195 (1997). - PubMed
    1. Lincoln G. A., Clarke I. J., Hut R. A. & Hazlerigg D. G. Characterizing a mammalian circannual pacemaker. Science 314, 1941–1944 (2006). - PubMed
    1. Reiter R. J., Gultekin F., Manchester L. C. & Tan D. X. Light pollution, melatonin suppression and cancer growth. J. Pineal Res. 40, 357–358 (2006). - PubMed
    1. Jung B. & Ahmad N. Melatonin in cancer management: Progress and promise. Cancer Res. 66, 9789–9793 (2006). - PubMed

Publication types